|
1
|
Seethala RR: Salivary gland tumors:
Current concepts and controversies. Surg Pathol Clin. 10:155–176.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dunn LA, Ho AL, Laurie SA and Pfister DG:
Unmet needs for patients with salivary gland cancer. Oral Oncol.
60:142–145. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Adelstein DJ, Koyfman SA, El-Naggar AK and
Hanna EY: Biology and management of salivary gland cancers. Semin
Radiat Oncol. 22:245–253. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Keller G, Steinmann D, Quaas A, Grunwald
V, Janssen S and Hussein K: New concepts of personalized therapy in
salivary gland carcinomas. Oral Oncol. 68:103–113. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Seethala RR and Stenman G: Update from the
4th edition of the world health organization classification of head
and neck tumours: Tumors of the salivary gland. Head Neck Pathol.
11:55–67. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dillon PM, Chakraborty S, Moskaluk CA,
Joshi PJ and Thomas CY: Adenoid cystic carcinoma: A review of
recent advances, molecular targets, and clinical trials. Head Neck.
38:620–627. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liu J, Shao C, Tan ML, Mu D, Ferris RL and
Ha PK: Molecular biology of adenoid cystic carcinoma. Head Neck.
34:1665–1677. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Moskaluk CA: Adenoid cystic carcinoma:
Clinical and molecular features. Head Neck Pathol. 7:17–22. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Coca-Pelaz A, Rodrigo JP, Bradley PJ,
Vander Poorten V, Triantafyllou A, Hunt JL, Strojan P, Rinaldo A,
Haigentz M Jr, Takes RP, et al: Adenoid cystic carcinoma of the
head and neck-an update. Oral Oncol. 51:652–661. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bell D and Hanna EY: Head and neck adenoid
cystic carcinoma: What is new in biological markers and treatment?
Curr Opin Otolaryngol Head Neck Surg. 21:124–129. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bell D and Hanna EY: Salivary gland
cancers: Biology and molecular targets for therapy. Curr Oncol Rep.
14:166–174. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ho AS, Kannan K, Roy DM, Morris LG, Ganly
I, Katabi N, Ramaswami D, Walsh LA, Eng S, Huse JT, et al: The
mutational landscape of adenoid cystic carcinoma. Nat Genet.
45:791–798. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Stephens PJ, Davies HR, Mitani Y, Van Loo
P, Shlien A, Tarpey PS, Papaemmanuil E, Cheverton A, Bignell GR,
Butler AP, et al: Whole exome sequencing of adenoid cystic
carcinoma. J Clin Invest. 123:2965–2968. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rettig EM, Talbot CC Jr, Sausen M, Jones
S, Bishop JA, Wood LD, Tokheim C, Niknafs N, Karchin R, Fertig EJ,
et al: Whole-genome sequencing of salivary gland adenoid cystic
carcinoma. Cancer Prev Res. 9:265–274. 2016.
|
|
15
|
Drier Y, Cotton MJ, Williamson KE,
Gillespie SM, Ryan RJ, Kluk MJ, Carey CD, Rodig SJ, Sholl LM,
Afrogheh AH, et al: An oncogenic MYB feedback loop drives alternate
cell fates in adenoid cystic carcinoma. Nat Genet. 48:265–272.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yin LX and Ha PK: Genetic alterations in
salivary gland cancers. Cancer. 122:1822–1831. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mitani Y, Liu B, Rao PH, Borra VJ, Zafereo
M, Weber RS, Kies M, Lozano G, Futreal PA, Caulin C, et al: Novel
MYBL1 gene rearrangements with recurrent MYBL1-NFIB
fusions in salivary adenoid cystic carcinomas lacking t(6;9)
translocations. Clin Cancer Res. 22:725–733. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ferrarotto R, Heymach JV and Glisson BS:
MYB-fusions and other potential actionable targets in adenoid
cystic carcinoma. Curr Opin Oncol. 28:195–200. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Grünewald I, Vollbrecht C, Meinrath J,
Meyer MF, Heukamp LC, Drebber U, Quaas A, Beutner D, Hüttenbrink
KB, Wardelmann E, et al: Targeted next generation sequencing of
parotid gland cancer uncovers genetic heterogeneity. Oncotarget.
6:18224–18237. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang K, Russell JS, McDermott JD, Elvin
JA, Khaira D, Johnson A, Jennings TA, Ali SM, Murray M, Marshall C,
et al: Profiling of 149 salivary duct carcinomas, carcinoma ex
pleomorphic adenomas, and adenocarcinomas, not otherwise specified
reveals actionable genomic alterations. Clin Cancer Res.
22:6061–6068. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ettl T, Schwarz-Furlan S, Haubner F,
Müller S, Zenk J, Gosau M, Reichert TE and Zeitler K: The
PI3K/AKT/mTOR signalling pathway is active in salivary gland cancer
and implies different functions and prognoses depending on cell
localisation. Oral Oncol. 48:822–830. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ettl T, Baader K, Stiegler C, Müller M,
Agaimy A, Zenk J, Kühnel T, Gosau M, Zeitler K, Schwarz S and
Brockhoff G: Loss of PTEN is associated with elevated EGFR and HER2
expression and worse prognosis in salivary gland cancer. Br J
Cancer. 106:719–726. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Griffith CC, Seethala RR, Luvison A,
Miller M and Chiosea SI: PIK3CA mutations and PTEN
loss in salivary duct carcinomas. Am J Surg Pathol. 37:1201–1207.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu H, Du L, Wang R, Wei C, Liu B, Zhu L,
Liu P, Liu Q, Li J, Lu SL, et al: High frequency of loss of PTEN
expression in human solid salivary adenoid cystic carcinoma and its
implication for targeted therapy. Oncotarget. 6:11477–11491.
2015.PubMed/NCBI
|
|
25
|
Cong W, Liu B, Liu S, Sun M, Liu H, Yang
Y, Wang R and Xiao J: Implications of the Wnt5a/CaMKII pathway in
retinoic acid-induced myogenic tongue abnormalities of developing
mice. Sci Rep. 4:60822014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
He W, Li AG, Wang D, Han S, Zheng B,
Goumans MJ, Ten Dijke P and Wang XJ: Overexpression of Smad7
results in severe pathological alterations in multiple epithelial
tissues. EMBO J. 21:2580–2590. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Puisieux A, Brabletz T and Caramel J:
Oncogenic roles of EMT-inducing transcription factors. Nat Cell
Biol. 16:488–494. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Xu J, Lamouille S and Derynck R:
TGF-beta-induced epithelial to mesenchymal transition. Cell Res.
19:156–172. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Song MS, Salmena L and Pandolfi PP: The
functions and regulation of the PTEN tumour suppressor. Nat Rev Mol
Cell Biol. 13:283–296. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li D and Roberts R: WD-repeat proteins:
Structure characteristics, biological function, and their
involvement in human diseases. Cell Mol Life Sci. 58:2085–2097.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan
A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, et al: The
epithelial-mesenchymal transition generates cells with properties
of stem cells. Cell. 133:704–715. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Adams A, Warner K and Nör JE: Salivary
gland cancer stem cells. Oral Oncol. 49:845–853. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Takada M, Zhang W, Suzuki A, Kuroda TS, Yu
Z, Inuzuka H, Gao D, Wan L, Zhuang M, Hu L, et al: FBW7 loss
promotes chromosomal instability and tumorigenesis via cyclin
E1/CDK2-mediated phosphorylation of CENP-A. Cancer Res.
77:4881–4893. 2017.PubMed/NCBI
|
|
34
|
Kitagawa K and Kitagawa M: The SCF-type E3
ubiquitin ligases as cancer targets. Curr Cancer Drug Targets.
16:119–129. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wu Y, Diao P, Li Z, Zhang W, Wang D, Wang
Y and Cheng J: Overexpression of WD repeat domain 5 associates with
aggressive clinicopathological features and unfavorable prognosis
in head neck squamous cell carcinoma. J Oral Pathol Med.
47:502–510. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sun Y, Cao L, Sheng X, Chen J, Zhou Y,
Yang C, Deng T, Ma H, Feng P, Liu J, et al: WDR79 promotes the
proliferation of non-small cell lung cancer cells via USP7-mediated
regulation of the Mdm2-p53 pathway. Cell Death Dis. 8:e27432017.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Meisinger C, Prokisch H, Gieger C, Soranzo
N, Mehta D, Rosskopf D, Lichtner P, Klopp N, Stephens J, Watkins
NA, et al: A genome-wide association study identifies three loci
associated with mean platelet volume. Am J Hum Genet. 84:66–71.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wang Q, Ma C and Kemmner W: Wdr66 is a
novel marker for risk stratification and involved in
epithelial-mesenchymal transition of esophageal squamous cell
carcinoma. BMC Cancer. 13:1372013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Nieto MA: Epithelial plasticity: A common
theme in embryonic and cancer cells. Science. 342:12348502013.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
De Craene B and Berx G: Regulatory
networks defining EMT during cancer initiation and progression. Nat
Rev Cancer. 13:97–110. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Bowen KA, Doan HQ, Zhou BP, Wang Q, Zhou
Y, Rychahou PG and Evers BM: PTEN loss induces epithelial -
mesenchymal transition in human colon cancer cells. Anticancer Res.
29:4439–4449. 2009.PubMed/NCBI
|
|
42
|
Labelle M, Begum S and Hynes RO: Direct
signaling between platelets and cancer cells induces an
epithelial-mesenchymal-like transition and promotes metastasis.
Cancer Cell. 20:576–590. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Gay LJ and Felding-Habermann B:
Contribution of platelets to tumour metastasis. Nat Rev Cancer.
11:123–134. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Hollander MC, Blumenthal GM and Dennis PA:
PTEN loss in the continuum of common cancers, rare syndromes and
mouse models. Nat Rev Cancer. 11:289–301. 2011. View Article : Google Scholar : PubMed/NCBI
|
